Evidence map›Paper›PMID 39541127›Full record

ArticleJAMA ophthalmology2025

Performance of Polygenic Risk Scores for Primary Open-Angle Glaucoma in Populations of African Descent.

Jennifer M Chang-Wolf, Tyler G Kinzy, Sjoerd J Driessen, Lauren A Cruz, Sudha K Iyengar, Neal S Peachey, Tin Aung, Chiea Chuen Khor, Susan E Williams, Michele Ramsay and 8 more

Abstract readMulticenter Study
In one paragraph

Article in JAMA ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Jennifer M Chang-WolfDepartment of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.
Tyler G KinzyCleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio.
Sjoerd J DriessenDepartment of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.
Lauren A CruzCleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio.
Sudha K IyengarCleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio.
Neal S PeacheyResearch Service, VA Northeast Ohio Healthcare System, Cleveland, Ohio.
Tin AungSingapore Eye Research Institute, Singapore.
Chiea Chuen KhorGenome Institute of Singapore, Agency for Science, Technology and Research, Singapore.
Susan E WilliamsDivision of Ophthalmology, Department of Neurosciences, University of the Witwatersrand, Johannesburg, South Africa.
Michele RamsaySydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Olusola OlawoyeDepartment of Ophthalmology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Adeyinka AshayeDepartment of Ophthalmology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Caroline C W KlaverDepartment of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.
Michael A HauserDepartment of Ophthalmology, Duke University, Durham, North Carolina.
Alberta A H J ThiadensDepartment of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.
Jessica N Cooke BaileyCleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio.
Pieter W M BonnemaijerDepartment of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.
Genetics in Glaucoma Patients of African Descent (GIGA) Study GroupGenetics of Glaucoma in People of African Descent (GGLAD) Study GroupMillion Veteran Program (MVP)

Funding

Prioritizing diversity in polygenic risk prediction of primary open-angle glaucomaR01EY033829 · NEI · EAST CAROLINA UNIVERSITY · PI Jessica N Cooke Bailey · 2022 to 2026
$3.6M
Module 3: Gene Expression/ProteomicsP30EY031631 · NEI · AUGUSTA UNIVERSITY · PI Xingjun Fan · 2020 to 2026
$3.6M
Gene Discovery in Familial KeratoconusR01EY023242 · NEI · DUKE UNIVERSITY · PI LIU, YUTAO · 2013 to 2023
$3.4M
Estrogen and its Receptor in Intraocular Pressure RegulationR01EY032960 · NEI · MAYO CLINIC ROCHESTER · PI Yutao Liu · 2023 to 2026
$1.6M
Long Noncoding RNA lncLOXL1 and Exfoliation Syndrome.R21EY028671 · NEI · AUGUSTA UNIVERSITY · PI LIU, YUTAO · 2018 to 2019
$467k
MIR182 and Ocular Hypertension.R21EY033961 · NEI · AUGUSTA UNIVERSITY · PI LIU, YUTAO · 2023 to 2024
$424k
NEI NIH HHS P30 EY031631NEI NIH HHS R01 EY032960NEI NIH HHS R01 EY033829NEI NIH HHS R21 EY028671NEI NIH HHS R21 EY033961
6 · The paper itself

Abstract

Importance: Primary open-angle glaucoma (POAG) polygenic risk scores (PRSs) continue to be evaluated in primarily European-ancestry populations despite higher prevalence and worse outcomes in African-ancestry populations. Objective: To evaluate how established POAG PRSs perform in African-ancestry samples from the Genetics in Glaucoma Patients of African Descent (GIGA), Genetics of Glaucoma in Individuals of African Descent (GGLAD), and Million Veteran Program (MVP) datasets and compare these with European-ancestry samples. Design, Setting, and Participants: This was a multicenter, cross-sectional study of POAG cases and controls from Tanzania, South Africa, Nigeria, Ghana, and the US. Included were individuals of African descent from South Africa and Tanzania from the GIGA dataset; individuals of African descent from Ghana, Nigeria, and the US from the GGLAD dataset; and individuals of African or European descent from the US in the MVP dataset. Data were analyzed from January 2022 to July 2023. Exposures: Three PRSs derived from large meta-analyses of European and Asian populations, namely Gharahkhani et al (Gharahkhani PRS), Han et al (Han PRS), and Craig et al (Craig PRS). Main Outcomes and Measures: Odds ratios (ORs) for POAG risk stratification comparing the highest and lowest quintiles; area under the receiver operating characteristic curve (AUROC), and liability coefficient of determination (R2) for the addition of PRS to a baseline of age, sex, and first 5 principal components. Results: A total of 11 673 cases and 66 432 controls were included in this study across 7 ancestral groups. Mean (SD) age of the total participants was 76.9 (8.7) years, with 74 304 males (95.1%). The following were included in each dataset: GIGA (663 cases, 476 controls), GGLAD (1471 cases, 1482 controls), and MVP (9559 cases, 64 474 controls). Increases in ORs were found for the highest POAG risk quintile ranging from an OR of 1.68 (95% CI, 1.17-2.43) in Ghanaians to 7.05 (95% CI, 2.73-19.6) in the South African multiple ancestry group (which derives from at least 5 distinct ancestral groups: Khoisan, Bantus, Europeans, Indians, and Southeast Asians) with the Gharahkhani PRS. The Han PRS showed OR increases for the highest POAG risk quintile ranging from 2.27 (95% CI, 1.49-3.47) in African American individuals in the GGLAD dataset to 7.24 (95% CI, 6.47-8.12) in Europeans. The Craig PRS predicted OR increases in the highest quintile for all groups ranging from 1.51 (95% CI, 1.05-2.18) in Ghanaians to 6.31 (95% CI, 5.67-7.04) in Europeans. However, AUROC and R2 increases above baseline were lower for all African-ancestry compared with European-ancestry groups in the 3 tested PRSs. Conclusions and Relevance: In this cross-sectional study, despite some improvements in OR-based risk stratification using the Gharahkhani PRSs, Han PRSs, and Craig PRSs, consistently lower improvements in AUROC and R2 for African-ancestry compared with European-ancestry groups highlight the need for risk prediction models tailored to diverse populations.

Indexed as

Black PeopleGenetic Predisposition to DiseaseGlaucoma, Open-AngleMultifactorial InheritanceAgedCross-Sectional StudiesFemaleGenetic Risk ScoreGhanaHumansMaleMiddle AgedPolymorphism, Single NucleotideRisk AssessmentRisk FactorsROC Curve

Identifiers

PMID39541127
PMCPMC11565374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.